Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:GEMP NASDAQ:GRTX NASDAQ:NERV NASDAQ:STML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$9.22+3.0%$7.94$2.32▼$9.89$498.73M2.93450,932 shs406,246 shsGEMPGemphire Therapeutics$0.98+2.0%$4.97$0.24▼$1.49$14.58M2.82127,174 shs22,223 shsGRTXGalera Therapeutics$0.02-2.1%$0.02$0.02▼$0.06$1.81M1.98103,722 shs294,201 shsNERVMinerva Neurosciences$4.70-3.5%$2.54$1.15▼$12.46N/A-0.39.25 million shs866,808 shsSTMLStemline Therapeutics$11.83$11.83$3.21▼$18.22$621.21M1.781.52 million shs1,084 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics0.00%+2.56%+8.47%+18.05%+183.69%GEMPGemphire Therapeutics+1.97%+0.75%-6.67%+39.00%-65.97%GRTXGalera Therapeutics0.00%+40.72%+30.56%-6.00%-55.74%NERVMinerva Neurosciences0.00%+88.76%+117.59%+120.66%+91.84%STMLStemline Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$9.22+3.0%$7.94$2.32▼$9.89$498.73M2.93450,932 shs406,246 shsGEMPGemphire Therapeutics$0.98+2.0%$4.97$0.24▼$1.49$14.58M2.82127,174 shs22,223 shsGRTXGalera Therapeutics$0.02-2.1%$0.02$0.02▼$0.06$1.81M1.98103,722 shs294,201 shsNERVMinerva Neurosciences$4.70-3.5%$2.54$1.15▼$12.46N/A-0.39.25 million shs866,808 shsSTMLStemline Therapeutics$11.83$11.83$3.21▼$18.22$621.21M1.781.52 million shs1,084 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics0.00%+2.56%+8.47%+18.05%+183.69%GEMPGemphire Therapeutics+1.97%+0.75%-6.67%+39.00%-65.97%GRTXGalera Therapeutics0.00%+40.72%+30.56%-6.00%-55.74%NERVMinerva Neurosciences0.00%+88.76%+117.59%+120.66%+91.84%STMLStemline Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 2.71Moderate Buy$11.2021.48% UpsideGEMPGemphire Therapeutics 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/ANERVMinerva Neurosciences 1.50Reduce$5.006.38% UpsideSTMLStemline Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STML, GRTX, NERV, GEMP, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025FULCFulcrum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/21/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$20.0010/20/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/8/2025FULCFulcrum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025FULCFulcrum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)7/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M6.23N/AN/A$4.51 per share2.04GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ANERVMinerva NeurosciencesN/AN/A$0.21 per share22.49($3.67) per shareN/ASTMLStemline Therapeutics$43.22M14.37N/AN/A$3.26 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%10/29/2025 (Estimated)GEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AGRTXGalera Therapeutics-$59.08M-$0.19N/A∞N/AN/AN/A-99.34%12/11/2025 (Estimated)NERVMinerva Neurosciences$1.44M$1.483.18N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)STMLStemline Therapeutics-$76.82M-$1.83N/AN/AN/A-150.30%-48.14%-41.35%N/ALatest STML, GRTX, NERV, GEMP, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025NERVMinerva Neurosciences-$0.35N/AN/AN/AN/AN/A10/29/2025Q3 2025FULCFulcrum Therapeutics-$0.29N/AN/AN/AN/AN/A8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASTMLStemline TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A24.4224.42GEMPGemphire TherapeuticsN/A0.670.67GRTXGalera TherapeuticsN/A9.749.74NERVMinerva NeurosciencesN/A6.156.15STMLStemline TherapeuticsN/A7.437.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%GEMPGemphire Therapeutics17.53%GRTXGalera Therapeutics50.77%NERVMinerva Neurosciences34.56%STMLStemline Therapeutics75.80%Insider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.00%GEMPGemphire Therapeutics22.70%GRTXGalera Therapeutics12.90%NERVMinerva Neurosciences8.60%STMLStemline Therapeutics11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableNERVMinerva Neurosciences9N/AN/ANot OptionableSTMLStemline Therapeutics9252.51 millionN/AOptionableSTML, GRTX, NERV, GEMP, and FULC HeadlinesRecent News About These CompaniesStemline’s Promising Study on Elacestrant for Metastatic Breast CancerAugust 4, 2025 | tipranks.comStemline’s Promising Phase 3 Study on Elacestrant for Early Breast CancerJuly 9, 2025 | tipranks.comInsilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M dealJanuary 10, 2025 | fiercebiotech.comFMenarini bags blood cancer drug with $677M Stemline acquisitionAugust 5, 2024 | pharmaphorum.comPMenarini Group and Insilico Medicine Enter Global Exclusive License Agreement forJanuary 6, 2024 | newswire.caMenarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidateJanuary 4, 2024 | fiercebiotech.comFStemline Therapeutics describes new RET mutant inhibitors for cancerMay 6, 2023 | bioworld.comBNew Hormonal Treatment Orserdu Approved for Metastatic Breast CancerFebruary 19, 2023 | everydayhealth.comEStemline Therapeutics’ breast cancer treatment approvedFebruary 1, 2023 | labiotech.euLFDA Approves Stemline’s Orserdu for Several Forms of Breast CancerJanuary 31, 2023 | fdanews.comFStemline first to market with oral SERD for breast cancerJanuary 31, 2023 | pharmaphorum.comPTrade These 7 Stocks Under $10 for Huge ProfitsApril 10, 2022 | thestreet.comBreakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)October 26, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTML, GRTX, NERV, GEMP, and FULC Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$9.22 +0.27 (+3.02%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$9.22 -0.01 (-0.05%) As of 10/24/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Gemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-2.08%) As of 10/24/2025 01:38 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Minerva Neurosciences NASDAQ:NERV$4.70 -0.17 (-3.49%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.66 -0.04 (-0.85%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Stemline Therapeutics NASDAQ:STMLStemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
